Business Description
Medigene AG
ISIN : DE000A1X3W00
Share Class Description:
XTER:MDG1: Namen-Akt. nach KapitalherabsetzungCompare
Compare
Traded in other countries / regions
MDG1.GermanyMDG1.AustriaMDGEF.USAMDG1.Switzerland0QGJ.UK IPO Date
2000-06-30Description
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.65 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -20.27 | |||||
| Beneish M-Score | -3.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9 | |||||
| 3-Year EBITDA Growth Rate | 12.1 | |||||
| 3-Year EPS without NRI Growth Rate | 17.6 | |||||
| 3-Year FCF Growth Rate | 14.5 | |||||
| 3-Year Book Growth Rate | -26.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | -49.9 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.57 | |||||
| 9-Day RSI | 34.79 | |||||
| 14-Day RSI | 37.94 | |||||
| 6-1 Month Momentum % | 23.08 | |||||
| 12-1 Month Momentum % | 28.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.53 | |||||
| Quick Ratio | 2.53 | |||||
| Cash Ratio | 2.32 | |||||
| Days Sales Outstanding | 100.64 | |||||
| Days Payable | 138.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 1.09 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.77 | |||||
| Operating Margin % | -267.63 | |||||
| Net Margin % | -268.1 | |||||
| FCF Margin % | -261.57 | |||||
| ROE % | -54.97 | |||||
| ROA % | -38.65 | |||||
| ROIC % | -73.14 | |||||
| ROC (Joel Greenblatt) % | -264.21 | |||||
| ROCE % | -45.8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.52 | |||||
| PB Ratio | 1.87 | |||||
| Price-to-Tangible-Book | 3.35 | |||||
| EV-to-EBIT | -1.47 | |||||
| EV-to-Forward-EBIT | -1.99 | |||||
| EV-to-EBITDA | -1.62 | |||||
| EV-to-Forward-EBITDA | -1.99 | |||||
| EV-to-Revenue | 3.9 | |||||
| EV-to-Forward-Revenue | 2.14 | |||||
| EV-to-FCF | -1.66 | |||||
| Price-to-Median-PS-Value | 0.55 | |||||
| Price-to-Net-Current-Asset-Value | 4.97 | |||||
| Price-to-Net-Cash | 6.26 | |||||
| Earnings Yield (Greenblatt) % | -68.02 | |||||
| FCF Yield % | -42.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medigene AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.034 | ||
| EPS (TTM) (€) | -0.627 | ||
| Beta | 1.36 | ||
| Volatility % | 61.31 | ||
| 14-Day RSI | 37.94 | ||
| 14-Day ATR (€) | 0.153415 | ||
| 20-Day SMA (€) | 1.630277 | ||
| 12-1 Month Momentum % | 28.57 | ||
| 52-Week Range (€) | 1.281977 - 2.753876 | ||
| Shares Outstanding (Mil) | 25.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medigene AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medigene AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medigene AG Frequently Asked Questions
What is Medigene AG(XTER:MDG1)'s stock price today?
The current price of XTER:MDG1 is €1.44. The 52 week high of XTER:MDG1 is €2.75 and 52 week low is €1.28.
When is next earnings date of Medigene AG(XTER:MDG1)?
The next earnings date of Medigene AG(XTER:MDG1) is 2024-08-16 Est..
Does Medigene AG(XTER:MDG1) pay dividends? If so, how much?
Medigene AG(XTER:MDG1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers